Building a conducive environment for life science-based entrepreneurship and industry clusters

Journal of Commercial Biotechnology

Volumn 14, Issue 1, 2008, Pages 20-30

  Ahn, Mark J ^a   Meeks, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

INDUSTRIAL ECONOMICS; INNOVATION; INTERNATIONAL TRADE; INVESTMENTS; TECHNOLOGY;

BIOPHARMACEUTICAL INDUSTRY; LIFE SCIENCE-BASED ENTREPRENEURSHIP;

BIOTECHNOLOGY;

ARTICLE; ASIA; BIOMEDICINE; BIOTECHNOLOGY; COMMERCIAL PHENOMENA; DRUG INDUSTRY; EMPLOYMENT; ENVIRONMENTAL SUSTAINABILITY; EUROPE; GOVERNMENT; INTERNET; INVESTMENT; NORTH AMERICA; PACIFIC ISLANDS; POLICY;

EID: 37749026239     PISSN: 14628732     EISSN: None     Source Type: Journal    
DOI: 10.1057/palgrave.jcb.3050076     Document Type: Article

References (39)

1. BIO (Biotechnology Industry Organization) (2006). BIO 2005-2006: Guide to Biotechnology, BIO, www.bio.org, accessed 5th June 2007.
2. Burrill & Co. (2007). Biotech 2007 Life Sciences: A Global Transformation, Burrill Life Sciences Media Group, San Francisco.
3. Ernst & Young (2007). Beyond Borders: Global Biotechnology Report, EYGM Limited, www.ey.com, accessed 20th June 2007.
4. California Healthcare Institute (2006). California's Biomedical Industry 2006 Report, CHI/PricewaterhouseCoopers LLP, www.chi.com, accessed 5th May 2007.
5. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved. For the drugs that progress into human clinical trials the overall attrition rates is 11 per cent, with oncology at 5 per cent (although biopharmaceuticals tend to have a lower overall clinical approval success rate compared to traditional pharmaceutical firm products).
6. Kola, I. & Lands, J. (2004). Can the pharmaceutical industry reduce attrition rates. Nat. Rev. Drug Discover. 3, 711-715.
7. The Tufts Center for the Study of Drug Development (2007). Structuring clinical organization to improve R&D productivity, www.csdd.tufts.edu, accessed 2nd April, 07.
8. PhRMA (Pharmaceutical Research and Manufacturers of America (2006). Pharmaceutical Industry Profile 2006, PhRMA, Washington, DC.
9. Pisano, G. (2006). Can science be a business? Lessons from biotech. Harvard Business Review, 84(10), 114-125.
10. Hildreth, M. (2006). Beyond Borders: The Global Biotechnology Report - Strength and Stability: The American Perspective, EYGM Limited, www.ey.com, accessed 15th May 2007.
11. Ernst & Young (2006). Beyond Borders: A Global Perspective, EYGM Limited, www.ey.com, accessed 15th May 2007.
12. Dolan, A. (2005). Drug alliance alchemy, www.forbes.com, accessed 19th June, 2007.
13. Ahn, M., Vitale, F. & Tong, V. (2005). Biopharmaceutical alliances: It's all academic. Biopharmaceutical International, October, pp. 24-26.
14. GAO (Government Accounting Office (2006). New drug development: Science business, regulatory, and intellectual property issues cited as hampering drug development efforts, GAO, 07-49.
15. Roner, L. (2005). Forging strategic alliances with biotech partners, Eyeforpharma Briefing.
16. Longman, R. (2005). The dealmaking landscape, Windhover Information.
17. Porter, M. (1998). Clusters and the new economics of competition. Harvard Bus. Rev. 76, Boston.
18. Munnich, L. (2004). Knowledge clusters as a means of promoting regional economic development, Humphrey Institute of Public Affairs, University of Minnesota.
19. Marshall, A. (1890). Principles of Economics, Macmillan and Co., Ltd, London.
20. Schumpeter, J. (1942). Capitalism, Socialism and Democracy, Harper & Row, New York.
21. Romer, P. (1996). Science, economic growth and public policy, in Smith, B. and Barfield, C. (eds.), Technology, R&D, and the Economy, Brookings Institution and American Enterprise Institute, Washington, DC.
22. Solow, R. (1957). Technical change and the aggregate production function. Rev. Econ. Stat. 39(August), 312-320.
23. Saxenian, S. (1994). Regional Advantage: Culture and Competition in Silicon Valley and Route 128, Harvard University Press, Boston.
24. Porter, M. (1990). Competitive Advantage of Nations, Free Press, New York.
25. Waits, M. J. (2000). The added value of the industry cluster approach to economic analysis, strategy development, and service delivery. Econ. Dev. Quart. 14(1), 35-50.
26. Baptista, R. (2000). Do innovations diffuse faster within geographic clusters. Int. J. Ind. Org. 18, 515-535.
27. Bergman, E. M. & Fesser, E. J. (2000). Industrial and regional clusters: concepts and comparative applications, Regional Research Institute, West Virginia University.
28. Kumaramangalam, K. (2005). Do firms produce better quality research with greater academic collaboration? Academy of Management Proceedings, 11-15.
29. Ketels, C. (2003). The development of the cluster concept - present experiences and further developments, NRW Conference, Duisburg, Germany, 5 December, pp. 1-25.
30. DeVol, R. & Bedroussian, A. (2006). Mind to Market: A Global Analysis of University Biotechnology Transfer and Commercialization, Milken Institute, Santa Monica.
31. Plsek, P. & Wilson, T. (2001). Complexity, leadership, and management in healthcare organisations. BMJ 323, 746-749.
32. Hine, D. & Kapeleris, J. (2006). Innovation and Entrepreneurship in Biotechnology, An International Perspective: Concepts, Theories, and Cases, EE Publishing Ltd., Northampton, MA.
33. Battelle (2007). Growing the nation's bioscience sector: A regional perspective, www.bio.org, accessed 5th May 2007.
34. Pharmalinx, LLC (2007). Biotech: States of the industry, View on Biotechnology, www.pharmalinx.com, accessed 17th June 2007.
35. Bendis, R. (2005). The importance of networking in technology convergence, Innovation Philadelphia Conference, Philadelphia.
36. Kim & Higgins (2005). Where do alliances come from? The effects of upper echelons on alliance formation, Academy of Management Best Conference Paper 2005, BPS: J1.
37. Fair, B. (2007). Building a bioscience cluster. Gen. Eng. News 27(4), 2.
38. Davenport, S. (2005). Exploring the role of proximity in SME knowledge-acquisition. Res. Pol. 34, 683-701.
39. Ernst & Young (2006). In Through the Out Door: Exit Strategies in Challenging Times, EYGM Limited, www.ey.com, accessed 30th June 2007.